Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Stephan Stilgenbauer(Universität Ulm), Barbara Eichhorst(Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases), Johannes Schetelig(TU Dresden), Steven Coutré(Stanford Medicine), John F. Seymour(University of Melbourne), Talha Munir(St James's University Hospital), Soham D. Puvvada(University of Arizona), Clemens‐Martin Wendtner(München Klinik Schwabing), Andrew W. Roberts(University of Melbourne), Wojciech Jurczak(Jagiellonian University), Stephen P. Mulligan(University of Sydney), Sebastian Böttcher(University Hospital Schleswig-Holstein), Mehrdad Mobasher, Ming Zhu(AbbVie (United States)), Monali Desai(AbbVie (United States)), Brenda Chyla(AbbVie (United States)), Maria Verdugo(AbbVie (United States)), Sari H. Enschede(AbbVie (United States)), Elisa Cerri(AbbVie (United States)), Rod Humerickhouse(AbbVie (United States)), Gary Gordon(AbbVie (United States)), Michael Hallek(University of Cologne), William G. Wierda(The University of Texas MD Anderson Cancer Center)
Cited by 796Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis